EPZM News and Press, Epizyme Inc. From 03/02/21

Epizyme’s Next EPIsode: Vision for Rewriting Oncology Treatment with Epigenetics Showcased New Five-Year Corporate Strategy Preliminary Safety and Activity Data from Ongoing Clinical Trials for TAZVERIK ® Combinations in Follicular Lymphoma and Prostate Cancer ...

Morgan Stanley has downgraded Epizyme ([[EPZM]] -1.8%) to equal-weight from overweight, The firm highlights the pandemic impact on Tazverik market launch with the price target cut to ~$14.00 from $27.00 per share implying ~37.4% upside to the previous close.The methyltransferase inhibitor pre...

The Next EPIsode: Epizyme’s Vision for Rewriting Oncology Treatment with Epigenetics Event to Showcase Epizyme’s Five-Year Corporate Strategy, TAZVERIK ® (tazemetostat) Ongoing Development Plans and Advancements in the Company’s Epigenetic Pipelin...

Image source: The Motley Fool. Epizyme Inc (NASDAQ: EPZM) Q4 2020 Earnings Call Feb 23, 2021 , 8:00 a.m. ET Operator Continue reading For further details see: Epizyme Inc (EPZM) Q4 2020 Earnings Call Transcript

Call Start: 08:00 Call End: 09:00 Epizyme, Inc. (EPZM) Q4 2020 Earnings Conference Call February 23, 2021, 8:00 am ET Company Participants Bill Slattery - IR, W2O Group Rob Bazemore - President & CEO Paolo Tombesi - CFO Vicki Vakiener - CCO Matt Ros - EVP, Chief Strategy and Business Offi...

Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK ® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK® in ES and FL and Phase 1b Portion of Phase 1b/2 Cas...

Total Revenue of $8.4 Million for 4Q 2020; $15.8 Million for FY 2020 TAZVERIK ® Net Revenues of $4.5 Million for 4Q 2020; $11.5 Million for FY 2020 Safety Run-In Portion of Confirmatory Trials of TAZVERIK ® in ES and FL and Phase 2 Castration-Resistan...

Epizyme (NASDAQ:EPZM) is scheduled to announce Q4 earnings results on Tuesday, February 23rd, before market open.The consensus EPS Estimate is -$0.59 (flat Y/Y) and the consensus Revenue Estimate is $6.55M (+52.7% Y/Y).Over the last 2 years, EPZM has beaten EPS estimates 88% of the time and h...

Epizyme , (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results a...

Today, we do a deep dive on Epizyme for the first time since March of last year. The stock is one of the few in the market near its 52-week lows.  The name has become a 'battleground stock' among analysts as well. What is ahead for Epizyme in 2021?  We try to answer that...